Abstract
Data in this article presents the results of conventional cytogenetics and fluorescence in situ hybridization (FISH) analyses in 129 patients with confirmed MECOM rearrangement (https://doi.org/10.1016/j.cancergen.2019.03.002) [1]. Generally, the MECOM rearrangement has arisen through translocation, inversion, and insertion and/or unknown mechanism. In addition to the typical chromosomal aberrations, inv(3)(q21q26.2) and t(3; 3)(q21; q26.6) [2–4], over 50% of cases presented here exhibit a wide spectrum of MECOM rearrangement-driven, atypical chromosomal aberrations, including inv(3) with breakpoint other than 3q21; t(1; 3); t(2; 3); t(3; 6); t(3; 8); t(3; 12); t(3; 17); t(3; 21) as well as an insertion of 3q26.2 into different chromosomes. These cases are thoroughly characterized by karyotyping, interphase-, metaphase-, map-back FISH and whole chromosomal painting (WCP) analyses.
Keywords: MECOM rearrangement, Inversion, Insertion, Translocation, Fluorescence in situ hybridization (FISH)
Specifications Table
| Subject area | Biology |
| More specific subject area | tumor |
| Type of data | Table |
| How data was acquired | Microscope, The CytoVision 7.6 (Leica Biosystems) |
| Data format | Raw data |
| Experimental factors | Chromosomal analysis and FISH analysis on cultured bone marrow specimen by following standard clinical laboratory protocol |
| Experimental features | Conventional Cytogenetics and FISH analyses |
| Data source location | Houston, Texas, United State of America |
| Data accessibility | Data is with this article |
| Related research article | Z. Tang, G. Tang, S. Hu, K.P. Patel, C.C. Yin, W. Wang, P. lin, G.A. Toruner, C.Y. Ok, J Gu, X. Lu, J.D. Khoury and L.J. Medeiros. Deciphering the Complexities of MECOM Rearrangement-Driven Chromosomal Aberrations. Cancer Genet. 233–234 (2019) 21–31. https://doi.org/10.1016/j.cancergen.2019.03.002 |
Value of the data
|
1. Data
This is an intensive characterization of complexities of chromosomal aberrations involving 3q26.2/MECOM rearrangement in 129 cases with a variety of myeloid malignancies. The majority of cases with atypical and/or complex karyotype has been thoroughly analyzed by interphase-, metaphase-, map-back FISH, and/or whole chromosome painting (WCP). In addition to the results of conventional cytogenetics and FISH analyses, other general clinical information including age, gender, pathologic diagnosis and outcomes, are also included (Table 1). We believe that all these cases can be practically useful for scientists and/or pathologists in the field of cytogenetic and genomic diagnostics. They can be used as references for all newly encountered case with a putative 3q26.2 abnormality/MECOM rearrangement.
Table 1.
General information, karyotyping and MECOM FISH results in 129 cases of myeloid malignancies.
| Case# | Sex | Age (y) | Diagnosis | D/A | FU (m) | Karyotype results | FISH results |
|---|---|---|---|---|---|---|---|
| 1 | M | 70 | AML | D | 2 | 45,XY,inv(3)(p23q26.2),-7,add(8)(q24.1),del(20)(q11.2q13.1)[20] | ish inv(3)(p23q26.2)(3′MECOM+,5′MECOM+)[3].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[153/200] |
| 2 | F | 77 | AML | D | 1 | 43,X,-X,inv(3)(q13.3q26.2),del(5)(q22q35),add(6)(p21.1),-7,-17,-19,+mar[8]/43,idem,del(11)(p11.2)[3]/44,idem,+mar[3]/44,idem,i(5)(q10),+mar[2]/46,XX[4] | ish inv(3)(q13.3)(3′MECOM+)(q26.2)(5′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[172/200] |
| 3 | M | 67 | AML | D | 10 | 45,XY,inv(3)(q21q26.2),-7[3]. | ish inv(3)(q21)(5′MECOM+)(q26.2)(5′MECOM+,3′MECOM+)[3].nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[164/200] |
| 4 | M | 72 | AML | D | 13 | 46,XY,inv(3)(q21q26.2)[20] | ish inv(3)(q21)(5′MECOM+)(q26.2)(3′MECOM+)[1].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[76/200] |
| 5 | M | 77 | MDS, AML | D | 4 | 46,XY,inv(3)(q21q26.2)[20] | ish inv(3)(q21)(5′MECOM+)(q26.2)(3′MECOM+)[1].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[42/200] |
| 6 | M | 74 | MDS | D | 32 | 46,XY,inv(3)(q21q26.2)[20] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[127/200] |
| 7 | M | 55 | AML | D | 6 | 46,XY,inv(3)(q21q26.2)[19]/46,XY[1] | ish inv(3)(q21)(5′MECOM+)(q26.2)(3′MECOM+)[1].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[158/200]nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[37/200]nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[39/200] |
| 8 | F | 63 | MDS | D | 10 | 46,XX,inv(3)(q21q26.2)[20] | ish inv(3)(q21)(5′MECOM+)(q26.2)(3′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[114/200] |
| 9 | M | 68 | AML/MDS | D | 2 | 45,X,-Y[15]/45,idem,inv(3)(q21q26.2)[5] | ish inv(3)(q21; q26)(3′MECOM+,5′MECOM+)[1].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[24/200] |
| 10 | F | 66 | AML | D | 1 | 46,XX,inv(3)(q21q26.2)[20] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[109/200] |
| 11 | M | 41 | AML | D | 4 | 46,XY,inv(3)(q21q26.2)[15]/47,idem,+mar[2]/46,XY[3] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[36/200] |
| 12 | M | 22 | AML | D | 4 | 45,XY,inv(3)(q21q26.2),-7[20] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[110/200] |
| 13 | F | 29 | t-MDS | A, CR (SCT) | 37 | 46,XX,inv(3)(q21q26.2)[20] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[76/200] |
| 14 | M | 74 | AML/MDS | D | 0 | 46,XY,inv(3)(q21q26.2)[20] | ish inv(3)(q21)(5′MECOM+)(q26.2)(3′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[100/200] |
| 15 | M | 72 | MDS | D | 0 | 45,XY,inv(3)(q21q26.2),del(5)(q31q35),-7,del(12)(p11.2p13)[16]/45,idem,del(11) (p11.2)[2]/46,XY[2] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[102/200] |
| 16 | M | 46 | AML | D | 5 | 46,XY,inv(3)(q21q26.2) | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[146/200] |
| 17 | F | 68 | MDS, AML | D | 3 | 44,XX,-3,inv(3)(q21q26.2),del(5)(q13q33),der(6)t(3; 6)(q23; p23),add(7)(q22),del(12)(p11.2p13),-20[17]/45,XX,inv(3)(q21q26.2),del(5)(q13q33),add(7)(q22),del(12)(p11.2p13),-20[3] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[138/200] |
| 18 | F | 72 | AML | D | 3 | 46,XX,inv(3)(q21q26.2)[4]/46,idem,der(16)t(1; 16)(q21; q13)[15]/46,idem,del(X)(q21)[1] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[138/200] |
| 19 | M | 32 | AML | A, CR | 21 | 46,XY,inv(3)(q21q26.2)[16]/46,XY[4] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[17/201 |
| 20 | F | 27 | AML | D | 4 | 43∼45,XX,add(2)(q32),add(3)(q27),inv(3)(q21q26.2),del(5)(q22q35),-7,del(14)(q22)[cp20] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[174/200] |
| 21 | F | 49 | AML | D | 0 | 46,XX,inv(3)(q21q26.2)[2]/46,idem,der(X)del(X)(p22.1p22.3)add(X)(q24)[9]/45,idem,-7[9] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[32/200] |
| 22 | F | 77 | MDS | A, PR | 3 | 46,XX,inv(3)(q21q26.2),r(7)[20] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[85/200] |
| 23 | M | 77 | AML | A, PR | 17 | 47,XY,inv(3)(q21q26.2),del(7)(q22q34),+21[20] | nucish(3′MECOMx3,5′MECOMx2)(3′MECOM con 5′MECOMx2)[54/200] |
| 24 | M | 91 | MDS | D | 1 | 47,XY,inv(3)(q21q26.2),+8[20] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[90/200] |
| 25 | F | 57 | AML | D | 0 | 46,XX,inv(3)(q21q26.2)[15]/46,idem,add(2)(q11.2)[4]/46,idem,der(2)t(2; 11)(q11.2; q13)[1] | ish inv(3)(q21)(3′MECOM+)(q26.2)(5′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[145/200] |
| 26 | M | 80 | MDS | D | 1 | 45,XY,inv(3)(q21q26.2),-7[20] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[131/200] |
| 27 | F | 73 | polycythemia vera with MF-3 | D | 0 | 46,XX,t(12; 18)(q13; q21.1)[4]/46,idem,add(13)(q12)[6]/46,idem,inv(3)(q21q26.2)[4]/46,idem,del(13)(q12q22)[3]/46,idem,add(6)(p21)[2]/45,idem,dic(6; 11)(p21; p11.2),add(7)(p22)[1] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[24/200]/(MECOMx4)[17/200] |
| 28 | F | 39 | AML | A, PR (SCT) | 11 | 46,XX,inv(3)(q21q26.2)[20] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[140/200] |
| 29 | M | 48 | AML | A, CR (SCT) | 7 | 45,XY,inv(3)(q21q26.2),-7[19]/46,XY[1] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[117/200] |
| 30 | M | 17 | AML | A, NR | 7 | 45,XY,inv(3)(q21q26.2),-7[18]/45,idem,+2mar[cp2] | ish inv(3)(q21)(3′MECOM+)(q26.2)(5′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[146/200] |
| 31 | M | 78 | AML | D | 4 | 45,XY,inv(3)(q21q26.2),-7,inv(9)(p12q13)[9]/46,XY,inv(9)(p12q13)[11] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[94/200] |
| 32 | F | 70 | MDS | D | 1 | 46,XX,inv(3)(q21q26.2)[20] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[103/200] |
| 33 | M | 52 | AML | A, PR | 4 | 46,XY,inv(3)(q21q26.2),t(7; 9)(p15; p23)[20] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[124/200] |
| 34 | M | 67 | AML | D | 2 | 45,X,-Y,inv(3)(q21q26.2)[20] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[147/200] |
| 35 | M | 65 | t-MDS; metastatic PROSTATIC ADENOCARCINOMA | A, PR | 2 | 42∼49,Y,add(X)(p22),inv(3)(q21q26.2),-4,-5,del(5)(q31q35),-7,-8,-9,add(11)(p15),-12,add(12)(p13),+14,+15,-16,del(17)(p12),-19,-21,+2∼8 mar[cp20] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[15/200] |
| 36 | F | 45 | AML | A, PR | 1 | 46,XX,inv(3)(q21q26.2)[14]/46,XX[6] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[68/200] |
| 37 | F | 53 | AML | A, NR | 0 | 45,XX,inv(3)(q21q26.2),-7[19]/46,idem,dup(1)(q25q32),-14,-16,+3mar[1] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[135/200] |
| 38 | M | 63 | CML, BP | A, PR | 11 | 46,XY,t(9; 22)(q34; q11.2)[5]/46,idem,inv(3)(q21q26.2)[10]/46,idem,inv(16)(p13.1q22)[5] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[43/200] |
| 39 | F | 45 | CML, CP | D | 5 | 46,XX,inv(3)(q21q26.2),t(9; 22)(q34; q11.2)[4]/46,idem,add(4)(q22),+12,-17,-17,+21[1]/46,XX[5] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[126/200] |
| 40 | M | 61 | CML, BP/AML | D | 12 | 46,XY,inv(3)(q21q26.2),t(6; 13)(q13; q34),t(9; 22)(q34; q11.2),t(16; 17)(q13; q25)[19]/46,XY[1] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[104/200] |
| 41 | F | 46 | CML, BP | A, PR | 1 | 45,XX,inv(3)(q21q26.2),-7,t(9; 22)(q34; q11.2),-15,+mar[10]/46,idem,+mar[7]/46,idem,+8[1]/45,XX,t(1; 2)(p34; p25),inv(3)(q21q26.2),-7,t(9; 22)[2] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[115/200] |
| 42 | M | 37 | CML, CP | A, PR | 8 | 46,XY,inv(3)(q21q26.2),t(9; 22)(q34; q11.2)[17]/46,XY[1] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[171/200] |
| 43 | M | 41 | t-AML | D | 9 | 46,XY,inv(3)(q21q26.2)[3]/45,idem,-7[16]/46,XY[1] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[53/200]nucish(MECOMx2)[200]nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[15/200] |
| 44 | F | 56 | AML/MDS | D | 5 | 46,XX,inv(3)(q21q26.2)x2[1]/45,XX,idem,-7[14]/46,XX[5] | ish inv(3)(q21)(5′MECOM+)(q26.2)(3′MECOM+)x2[3].nucish(MECOMx2)(3′MECOM sep 5′MECOMx2)[85/200] |
| 45 | F | 70 | AML | D | 4 | 46,XX,inv(3)(q21q26)x2[16]/46,idem,+1,der(1; 15)(q10; q10)[4] | ish inv(3)(q21)(3′MECOM+)(q26.2)(5′MECOM+)x2[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx2)[40/200] |
| 46 | M | 44 | MDS, AML | A, PR | 3 | 43∼45,XY,inv(3)(p21q28),inv(3)(q21q26.2),del(5)(q22q35),-7,-12,der(12; 14)(q10; q10),-14,-17,del(17)(p12),+1∼3mar[cp20] | ish inv(3)(q21)(3′MECOM+)(q26.2)(5′MECOM+)[2]/inv(3)(p21q28)(MECOM+)[1].nuc ish(MECOMx2)(3′MECOM sep 5′MECOMx1)[44/200] |
| 47 | F | 46 | CML, BP | A, PR | 5 | 46,XX,add(2)(q33),inv(3)(q26.2q28),t(9; 22)(q34; q11.2)[4]/47,idem,+8[8] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[51/200] |
| 48 | F | 83 | MDS | D | 2 | 44,XX,der(3)del(3)(p25)inv(3)(q21q26.2)add(3)(q26.2),-5,-7,-12,add(17)(p11.2),i(22)(q10),+r[6]/43,XX,der(3)inv(3)(q21q26.2)add(3)(q26.2),-5,-7,-15,add(17)(p11.2),i(22)(q10),+mar[6]/42∼45,XX,der(3)inv(3)(q21q26.2)add(3)(q26.2),-5,-7,-12,add(17)(p11.2),-20,i(22)(q10),+mar[cp6]/46,XX[2] | ish der(3)inv(3)(q21)(3′MECOM-)(q26.2)(5′MECOM+)add(3)(q26.2)[5].nucish(3′MECOMx1,5′MECOMx2)(3′MECOM con 5′MECOMx1)[86/200] |
| 49 | M | 65 | MDS | D | 11 | 45,XY,der(3)ins(3; ?)(q21; ?)inv(3)(q21q26.2),der(5)del(5)(q13q33)t(5; 11)(q35; q22),-7,der(11)t(5; 11),inv(12)(p12q21),add(13)(q34),-15,del(20)(q11.2q13.3),+mar,+2∼5dmin[17]/46,XY[2] | ish der(3)ins(3; ?)(q21; ?)inv(3)(q21)(5′MECOM+)q26.2)(3′MECOM+)[2].nuc ish(MECOMx2)(3′MECOM sep 5′MECOMx1)[21/200] |
| 50 | F | 57 | AML | D | 11 | 46,XX,der(3)t(3; 11)(q13.2; q21),der(11)t(3; 11)inv(3)(q21q26.2),del(12)(p13)[18]/46,idem[cp2] | ish der(3)t(3; 11)(q13.2; q21)(MECOM-),der(11)t(3; 11)inv(3)(q21)(3′MECOM+)(q26.2)(5′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[145/200]. MLL FISH negative |
| 51 | M | 69 | AML | D | 4 | 46,XY,der(3)t(3; 14)(p13; q32)inv(3)(q21q26.2),der(14)t(3; 14)[18]/46,idem,del(7)(p12)[2] | ish der(3)t(3; 14)(p13; q32)inv(3)(q21)(5′MECOM+)(q26.2)(3′MECOM+)[4].nuc ish(MECOMx2)(3′MECOM sep 5′MECOMx1)[132/200] |
| 52 | M | 56 | MDS | D | 8 | 46,XY,-7,+mar[1]/46,sl,der(3)t(3; 3)(p21; q13),der(3)t(3; 3)inv(3)(q21q26.2)[9]/47,sdl,+mar[7]/47∼48, sl,+1∼2mar[cp3] | ish der(3)t(3;3)(p21; q13)(MECOM-),der(3)t(3;3)inv(3)(q21q26.2)(3′MECOM+,5′MECOM+,MECOM+)[2].nuc ish(MECOMx2)(3′MECOM sep 5′MECOMx1)[107/200] |
| 53 | F | 45 | AML/MDS | A, CR (SCT) | 55 | 46,XX,t(1; 3)(q32; q26.2)[20] | ish t(1; 3)(q32; q26)(5′MECOM+; 3′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[180/200]nucish(MECOMX2)[200] |
| 54 | F | 65 | donor cell AML | A, PR | 1 | //46,XY,der(2)t(2; 3)(q21; q26.2),der(3; 3)(q10; q10)add(3)(q26.2)t(2; 3),del(20)(q11.2q13.3)[12] | ish der(2)t(2; 3)(p21; q26.2)(5′MECOM+),der(3; 3)(q10; q10)add(3)(q26.2)(3′MECOM+)t(2; 3)(3′MECOM+)[1].nuc ish(3′MECOMx3,5′MECOMx2)(3′MECOM con 5′MECOMx1)[176/200]/(MECOMx2)(3′MECOM sep 5′MECOMx1)[24/200] |
| 55 | F | 77 | MDS + CML | D | 1 | 47,XX,t(2; 3)(p16; q26.2),del(7)(q22q34),t(9; 22)(q34; q11.2),+21[20] | ish t(2; 3)(p16; q26.2)(5′MECOM+; 3′MECOM+)[3].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[191/200] |
| 56 | F | 46 | MDS/AML | D | 23 | 46,XX,t(2; 3)(p21; q26.2)[20] | ish t(2; 3)(5′MECOM+; 3′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[185/200] |
| 57 | F | 69 | MDS/CMML | D | 12 | 46,XX,t(2; 3)(p21; q26.2)[20] | ish t(2; 3)(p21; q26.2)(5′MECOM+; 3′MECOM+)[5].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[175/200] |
| 58 | F | 80 | MDS | D | 4 | 45,XX,t(2; 3)(p21; q26.2),-7[2]/46,t(2; 3),r(7)(p21q11.2)[2]/46,XX[16] | ish t(2; 3)(p21; q26.2)(5′MECOM+; MECOM+)[1].nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[35/200] |
| 59 | F | 56 | CML, BP | D | 8 | 45,XX,t(2; 3)(p21; q26.2),-7,t(9; 22)(q34; q11.2)[19]/45,idem,add(6)(q21)[1] | ish t(2; 3)(p21; q26.2)(5′MECOM+; 3′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[190/200] |
| 60 | M | 65 | MDS/AML | D | 13 | 46,XY,t(2; 3)(p23; q26.2)[20] | ish t(2; 3)(5′MECOM+; 3′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[194/200] |
| 61 | M | 63 | AML | D | 1 | 46,XY,t(2; 3)(p23; q26.2),r(7)[20] | ish t(2; 3)(p23; q26.2)(5′MECOM+; MECOM+)[2].nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[172/200] |
| 62 | M | 53 | AML | D | 11 | 46,XY,t(2; 3)(p23; q26.2)[19]/47,idem,+21[1 | nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[158/200] |
| 63 | F | 38 | MDS | D | 6 | 46,XX,t(2; 3)(p23; q26.2)[5]/46,idem,-5,+r[13]/46,XX[2] | nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[172/200]nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[123/200] |
| 64 | F | 57 | AML | A, PR (SCT) | 8 | 46,XX,t(2; 3)(p23; q26.2),del(5)(q22q35)[20] | ish t(2; 3)(p23; q26.2)(5′MECOM+; MECOM+)[2].nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[197/200] |
| 65 | M | 39 | CML, CP | A, PR | 5 | 47,XY,+8[4]/46,X,-Y,+8[12]/46,XY,t(2; 3)(p23; q26.2),t(9; 22)(q34; q11.2)[4] | ish t(2; 3)(p23; q26.2)(5′MECOM+; MECOM+)[1].nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[11/200] |
| 66 | F | 51 | MDS | D | 22 | 46,XX,t(2; 3)(p23; q26.2)[17]/47,idem,+mar[2]/46,idem,der(18)t(1; 18)(q21; p11.2)[1] | nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[70/200]ish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[38/200]nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[95/200]nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[180/200]nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[178/200] |
| 67 | M | 52 | AML | A, NR | 5 | 45,XY,der(3)t(3; 3)(q21; q26.2),der(3)t(5; 17)(q22; p12)t(3; 5)(p12; q13)t(3; 3),t(4; 18)(p16; q21.1),-5,der(7)del(7)(p12)del(7)(q11.2),der(17)t(3; 7)(p22; q22)t(7; 17)(q32; p11.2),-20,+mar[20] | ish der(3)t(3; 3)(q21; q26.2)(5′MECOM+), der(3)t(5; 17)(q22; p12)t(3; 5)(p12; q13)t(3; 3)(MECOM+,MECOM+)[2].nuc ish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[200] |
| 68 | M | 73 | AML | D | 3 | 46,XY,t(3; 3)(q21; q26.2)[11]/45,idem,del(6)(q21),-7[7]/46,idem,del(7)(q22)[1]/45,idem,del(16)(p11.1)[1] | ish t(3; 3)(q21; q26.2)(3′MECOM+; MECOM+,5′MECOM+)[4].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[190/200] |
| 69 | F | 73 | MDS | D | 5 | 46,XX,del(5)(q13q33)[2]/46,idem,t(3; 3)(q21; q26.2),del(7)(q22q35)[18] | ish t(3; 3)(q21; q26.2)(5′MECOM+; MECOM+,3′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[174/200] |
| 70 | F | 74 | AML | D | 8 | 44∼45,XX,t(3; 3)(q21; q26.2),-7[cp3]/46,XX[17]. | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[36/200] |
| 71 | M | 18 | AML | A, NR | 7 | 45,XY,t(3; 3)(q21; q26.2),-7[18]/46,XY[2] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[36/200] |
| 72 | M | 65 | AML | A, NR | 4 | 43,XY,der(1)inv(1)(p22q32)add(1)(q32),t(3; 3)(q21; q26.2),del(5)(q31q35),-7,del(12)(p11.2),-14,-16,add(19)(q13.3),add(20)(q11.2)[20] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[74/200] |
| 73 | M | 40 | AML | A, NR | 0 | 45,XY,t(3; 3)(q21; q26.2),-7[8]/45,idem,+1,der(1; 15)(q10; q10),del(14)(q11.2q24)[2]/46,XY[1] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[62/200] |
| 74 | M | 58 | AML | D | 20 | 46,XY,t(3; 3)(q21; q26.2)[3]//46,XX[5] | ish t(3; 3)(3′MECOM+; MECOM+)[1]/nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[40/200] |
| 75 | F | 40 | AML | D | 0 | 47,XX,t(3; 3)(q26.2; q21),t(9; 22)(q34; q11.2),del(11)(p11.2p12),+19[11]/47,idem,del(8)(q12q23)[1]/47,XX,t(3; 3),del(8)(q12q23),t(9; 22)(q34; q11.2),del(11)(p12p15),der(19)t(19; 22)(p13.1; q11.2)t(9; 22),+19[4]/47∼48,XX,t(3; 3),der(7)t(7; 22)(q11.2; p11.2),der(9)t(9; 22),+19,der(22)t(7; 22)t(9; 22),+der(22)t(9; 22),+1∼2mar[cp5] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[193/200] |
| 76 | M | 19 | AML | D | 12 | 46,XY,t(3; 6)(q26.2; p23),der(4)t(3; 4)(q12; p16),del(5)(q13q33),add(18)(q23)[3]/46,XY,t(3; 6)(q26.2; p23),der(4)t(3; 4)(q12; p16),add(5)(q21)[1]/46,XY,t(3; 6)(q26.2; p23),der(4)t(3; 4)(q12; p16),add(5)(q21),der(7)t(3; 7)(q26.2; q36)[1]/46,XY[20] | ish t(3; 6)(q26.2; p23)(3′MECOM+; 5′MECOM+),der(4)t(3; 4)(q12; p16)(MECOM+),der(7)t(3; 7)(q26.2; q36)(MECOM+)[1].nuc ish(3′MECOMx3,5′MECOMx4)(3′MECOM con 5′MECOMx3)[11/200] |
| 77 | F | 64 | AML | A, NR | 0 | 46,XX,t(3; 6)(q26.2; q25)[20] | ish t(3; 6)(q26.2; q25)(3′MECOM+; 5′MECOM+)[2].nucish (MECOMx2)(3′MECOM sep 5′MECOMx1)[193/200] |
| 78 | M | 67 | MDS | D | 22 | 46,XY,t(3; 6)(q26.2; q26)[23] | ish t(3; 6)(q26.2; q26)(3′MECOM+; 5′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[195/200] |
| 79 | M | 70 | AML | D | 2 | 46,XY,t(3; 6)(q26.2; q26)[20] | ish t(3; 6)(q26.2; q26)(3′MECOM+; 5′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[190/200] |
| 80 | M | 66 | AML | D | 2 | 46,XY,t(3; 8)(q26.2; q24.1)[5]/45,idem,-7[10]/43∼45,idem,dup(1)(q12q25),-7,-13[cp5] | ish t(3; 8)(q26.2; q24.1)(3′MECOM+; 5′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[126/200]nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[16/200] (AB-14-24500) |
| 81 | F | 75 | MDS | A, NR | 7 | 46,XX,t(3; 8)(q26.2; q24.1)[20] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[186/200] |
| 82 | M | 21 | MDS, Fanconi's anemia | D | 8 | 46,XY,t(3; 8)(q26.2; q24.1),der(7)t(7; 8)(q22; q13)t(3; 8),der(22)t(1; 22)(q25; q13)[6]/46,idem,der(2)t(2; 21)(q37; q11.2)[11]/46,idem,del(2)(q31)[3] | ish t(3; 8)(q26.2; q24.1)(3′MECOM+; 5′MECOM+),der(7)t(7; 8)(q22; q13)t(3; 8)(5′MECOM+)[2].nuc ish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx1)[184] |
| 83 | M | 63 | AML | D | 0 | 46,XY,t(3; 8)(q26.2; q24.2)[16]/46,XY[4] | ish t(3; 8)(q26.2; q24.2)(3′MECOM+; 5′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[188/200] |
| 84 | M | 59 | AML | D | 3 | 46,XY,t(3; 8)(q26.2; q24.2)[20] | ish t(3; 8)(q26.2; q24.2)(3′MECOM+; 5′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[166/200] |
| 85 | F | 65 | AML | D | 1 | 45,XX,t(3; 8)(q26.2; q24),-7[17]/46,idem,+21[1]/47,idem,+21,+22[2] | ish t(3; 8)(3′MECOM+; 5′MECOM+)[3].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[195/200] |
| 86 | M | 48 | t-AML | D | 0 | 46,XY,t(3; 10; 21)(q26.2; p14; q22)[20] | ish t(3; 10; 21)(q26.2; p14; q22)(MECOM+; 5′MECOM+; MECOM-)[3].nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[166/200].isht(3; 10; 21)(q26.2; p14; q22)(wcp21+; wcp21-;wcp21+)[3] |
| 87 | M | 61 | AML | D | 12 | 45,XY,t(3; 12)(q26.2; p13),-7[2]/46,XY,idem,+mar[10]/45,idem,-5,add(8)(p23),+mar[7] | ish t(3; 12)(q26.2; p13)(3′MECOM+; 5′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[192/200] |
| 88 | M | 45 | AML | A, CR (SCT) | 70 | 46,XY,t(3; 12)(q26.2; p13)[10]/46,XY[10] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[54/200] |
| 89 | F | 45 | AML | A, PR (SCT) | 36 | 46,XX,t(3; 12)(q26.2; p13)[19]/46,XX[1] | ish t(3; 12)(q26.2; p13)(3′MECOM+; 5′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[176/200]nucish(MECOMx2)[200] (AB-15-11961) |
| 90 | F | 33 | AML | D | 5 | 45,XX,t(3; 12)(q26.2; p13),-7[20] | ish t(3; 12)(q26.1; p13)(3′MECOM+; 5′MECOM+)[1].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[200] |
| 91 | F | 63 | MDS | A, PR (SCT ) | 16 | 46,XX,t(3; 12)(q26.2; p13)[2]/46,XX[23] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[131/200] |
| 92 | F | 60 | AML | D | 2 | 46,XX,t(3; 12)(q26.2; p13)[3]/41∼45,idem,-22[cp6] | ish t(3; 12)(q26.2; p13)(5′ETV6+; 3′ETV6+)[2].nucish(ETV6x2)(5′ETV6 sep 3′ETV6x1)[120/200].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[106/200] |
| 93 | F | 38 | AML | A, NR | 4 | 46,XX,t(3; 12)(q26.2; p13),del(7)(q22q36)[18]/46,idem[cp2] | ish t(3; 12)(q26.2; p13)(MECOM+; 5′MECOM+)[2].nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[188/200] |
| 94 | F | 75 | t-AML | A, PR | 2 | 45,XX,t(3; 12)(q26.2; p13),-7,idic(22)(p11.2)[16]/46,XX[4] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[107/200] |
| 95 | M | 59 | CML, BP | D | 12 | 49,XY,t(3; 12)(q26.2; p13),+8,+8,+i(8)(q10),i(8)(q10)x2,t(9; 22)(q34; q11.2)[19]/46,XY | ish t(3; 12)(q26; p13)(5′ETV6+; 3′ETV6+,5′ETV6-)[3].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[104/200] |
| 96 | M | 28 | AML | A, PR | 0 | 45,XY,t(3; 12)(q26.2; p13),del(5)(q22q33),-7[20] | ish t(3; 12)(q26.2; p13)(3′MECOM+; 5′MECOM+)[1].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[82/200] |
| 97 | M | 32 | CML, BP | D | 6 | 46,XY,t(3; 17)(q26.2; q22),t(9; 22)(q34; q11.2)[20] | ish t(3; 17)(3′MECOM+; 5′MECOM+)[4].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[132/200] |
| 98 | F | 44 | CML, BP | D | 4 | 46,XX,t(3; 17)(q26.2; q22),t(9; 22)(q34; q11.2)[19]/47,idem,+der(22)t(9; 22)[1] | ish t(3; 17)(q26.2; q22)(MECOM+; 5′MECOM+)[4].nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[183/200] |
| 99 | M | 77 | t-MDS/AML, MM, | D | 17 | 45,XY,der(1)t(1; 17)(p36.1; q25),t(3; 17)(q26.2; q23),-7,del(20)(q13.1q13.3)[26] | ish t(3; 17)(5′MECOM+; 3′MECOM+)[3].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[172/200] |
| 100 | F | 47 | t-MDS | D | 3 | 46,XX,add(3)(q27),t(3; 17)(q26.2; q23)[3]/46,XX[17] | ish add(3)(q27)(MECOM+),t(3; 17)(q26.2; q23)(5′MECOM+; 3′MECOM+)[1].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[150/200] |
| 101 | M | 22 | AML | D | 10 | 47,XY,+X?c,t(3; 21)(q26.2; q22),del(13)(q12q14)[20] | ish t(3; 21)(q26.1; q22)(3′MECOM+,5′MECOM+)[2].nucish((MECOMx2)(3′MECOM sep 5′MECOMx1)[188/200]nucish(MECOMx2)[200]nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[178/200] |
| 102 | M | 75 | MDS + MCL | D | 7 | 46,XY,r(7)(p11.2q11.2),der(12)del(12)(p11.2p12)inv(12)(p13q21)[3]/46,idem,t(3; 21)(q26.2; q22)[2]/46,XY[2] | ish t(3; 21)(q26.2; q22)(5′MECOM+; 3′MECOM+)[1].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[84/200] |
| 103 | F | 59 | MDS | D (SCT) | 12 | 46,XX,t(3; 21)(q26.2; q22)[3] | ish t(3; 21)(3′MECOM+; 5′MECOM+).nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[104/200] |
| 104 | M | 65 | AML | D | 9 | 46,XY,t(9; 17)(p22; q25),t(15; 15)(q21; q26)[7]/46,XY,idem,inv(3)(p25q12)[1]/48,XY,t(3; 21)(q26.2; q22),+13,+14[3]/46,XY[9] | ish t(3; 21)(q26.2; q22)(3′MECOM+; 5′MECOM+)[3].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[17/200] |
| 105 | M | 82 | AML/MDS | D | 8 | 47,XY,t(3; 21)(q26.2; q22),+8[18]/48,idem,+mar[2] | ish t(3; 21)(q26.2; q22)(3′MECOM+; 5′MECOM+)[5].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[160/200] |
| 106 | M | 67 | MDS | D | 5 | 46,XY,t(3; 21)(q26.2; q22),add(7)(q22)[13]/46,XY[7] | ish t(3; 21)(q26.2; q22)(3′MECOM+; 5′MECOM+)[3].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[59/200] |
| 107 | F | 80 | AML | D | 15 | 46,XX,t(3; 21)(q26.2; q22)[1]/46,idem,t(2; 7)(q36; p15)[14]/46,XX[5] | nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECONx2)[191/200] |
| 108 | M | 46 | AML | D | 2 | 46,XY,t(3; 21)(q26.2; q22),der(7)t(1; 7)(q21; q22)[6]/46,idem,+der(13; 21)(q10; q10),der(13; 21)(q10; q10)[14] | ish t(3; 21)(q26.2; q22)(MECOM+; 5′MECOM+)[4].nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[181/200] |
| 109 | M | 78 | AML | D | 10 | 46,XY,der(7; 18)(p10; q10),+11[2]/46,idem,t(3; 21)(q26.2; q22)[5]/45,X,-Y[5]/46,XY[8] | ish t(3; 21)(q26.2; q22)(MECOM+; 5′MECOM+)[4].nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[50/200] |
| 110 | M | 75 | AML | A, NR | 6 | 46,XY,t(3; 21)(q26.2; q22)[6]45,idem,-7[4]/46,XY[10] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[163/200] |
| 111 | F | 63 | MDS | A, PR | 5 | 46,XX,t(3; 21)(q26.2; q22)[8]/46,idem,del(11)(p11.2)[5]/46,XX[4] | ish t(3; 21)(q26.2; q22)(MECOM+; 5′MECOM+)[2].nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[173/200] |
| 112 | F | 69 | MDS, AML | D | 0 | 46,XX,t(3; 21)(q26.2; q22),del(5)(q15q33),inv(9)(p12q13)[20] | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[175/200] |
| 113 | F | 53 | t-MDS/AML | A, PR | 3 | 45,XX,t(3; 21)(q26.2; q22),-7[20] | nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[40/200] |
| 114 | M | 71 | AML/MDS | A, NR | 2 | 46,XY,t(3; 21)(q26.2; q22)[15]/46,XY[5] | ish t(3; 21)(q26.2; q22)(MECOM+; 5′MECOM+)[3].nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[173/200].nucish(RUNX1T1x2,RUNX1x3)[165/200] |
| 115 | M | 39 | t-MDS | A, PR | 2 | 46,XY,t(3; 21)(q26.2; q22)[5]/46,idem,add(10)(p12)[1]/46,idem,inv(11)(p15q23)[1]/46,XY[13] | nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[176/200] |
| 116 | M | 63 | AML | D | 7 | 46,XY,add(2)(p21),-3,-3,del(5)(q13q33),+8,add(17)(p11.2),add(22)(q13),+der(?)ins(?; 3)(?; q26.2q26.2)[3]/47,idem,+16[6]/45∼57,XY,add(2)(p21),-3,-3,del(5)(q13q33),+8,add(11)(p15),+16,add(17)(p11.2),add(22)(q13),+1∼5mar[cp11] | ish der(17)t(3; 17)(q22; p12)(MECOM+),der(?)ins(?; 3)(?; q26.2q26.2)(MECOM dim)[2]/der(17)t(3; 17)(q22; p12)(MECOM+),der(?)ins(?; 3)(?; q26.2q26.2)(3′MECOM+)[1].nuc ish(MECOMx1,MECOM dimx1)[463/500]/(3′MECOMx2,5′MECOMx1)(3′MECOM con 5′MECOMx1)[19/500] |
| 117 | F | 69 | AML | D | 10 | 45,XX,der(1)ins(1; 3)(p22; q24q26.2)del(1)(q32),der(3)ins(1; 3)(p22; q24q26.2),del(5)(q22q33),-7,add(10)(p12)[19]/46,XX[1] | ish der(1)ins(1; 3)(p22; q24q26.2)del(1)(q32)(3′MECOM+),der(3)ins(1; 3)(3′MECOM-,5′MECOM+)[2].nuc ish(MECOMx2)(3′MECOM sep 5′MECOMx1)[194/200] |
| 118 | M | 18 | AML | D | 2 | 38∼44,X,-Y,i(1)(q10),add(2)(p23),der(3)dup(3)(q23q27)add(3)(q29),-5,del(5)(q22q35),der(7)t(1; 7)(q21; p15),-9,add(10)(q22),add(15)(p11.2),der(16)t(?; 16)(?; p12)ins(?; 3)(?; q26.2q26.2),add(17)(p11.2),-18,-19,-21,+1∼3mar[cp20] | ish der(3)dup(3)(q23q27)(MECOM++)add(3)(q29), der(16)t(?; 16)(?; p12)ins(?; 3)(?; q26.2q26.2)(5′MECOM+)[2].nucish(3′MECOMx3,5′MECOMx4)(3′MECOM con 5′MECOMx3)[189/200] |
| 119 | M | 53 | AML | D | 6 | 51,XY,del(3)(q26.2),+8,der(8)ins(8; 3)(q24.1; q26.2q26.2),t(9; 22)(q34; q11.2),add(11)(q23),+19,+20,+21,+der(22)t(9; 22)[20] | ish del(3)(q26.2)(3′MECOM+),der(8)ins(8; 3)(q24.1; q26.2q26.2)(5′MECOM+)[4].nuc ish(MECOMx2)(3′MECOM sep 5′MECOMx1)[195/200] |
| 120 | F | 73 | MDS | A, PR | 7 | 46,XX,ins(12; 3)(p13; q21q26.2)[11]/46,XX[9] | ish ins(12; 3)(p13; q21q26.2)(MECOM+; 5′MECOM+)[2].nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[64/200].nucish(5′ETV6x2,3′ETV6x1)(5′ETV6 con 3′ETV6x1)[60/200] |
| 121 | F | 39 | AML | D | 12 | 45,XX,ins(3; 3)(q21; q21q26.2),-7[14]//46,XY,inv(9)(p12q13)[6] | ish ins(3; 3)(q21; q21q26.2)(3′MECOM+,MECOM+; 5′MECOM+)[2].nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[79/200] |
| 122 | M | 70 | AML | D | 1 | 41∼44,XY,der(3)del(3)(q25q26.2)add(3)(q27),der(3)del(3)(q25q26.2)hsr(3)(q26.2),-4,-5,-6,add(7)(p15),-12,-17,-21,add(22)(q11.2),+der(?)ins(?; 3)(?; q26.2q29)dup(3)(q26.2q29),+1∼3mar[cp20] | ish der(3)del(3)(q25q26.2)add(3)(q27)(3′MECOM-,5′MECOM+),der(?)ins(?; 3)(?; q26.2q29)(5′MECOM+)dup(3)(q26.2q29)(5′MECOM+)[1]/der(3)del(3)(q25q26.2)hsr(3)(q26.2)(3′MECOM-,5′MECOM amp)[2].nucish(MECOMx1,5′MECOM amp)[48/200]/(3′MECOMx1,5′MECOMx3∼6)(3′MECOM con 5′MECOMx1)[90/200] |
| 123 | M | 50 | AML | D | 7 | 44,XY,add(4)(p16),del(5)(q13q33),add(8)(p21),add(8)(q24),add(17)(p12),-18,-19,-20,+mar[12]/44,XY,add(4)(p16),del(5)(q13q33),add(8)(q24),add(17)(p12),-18,-19,-20,+22[4]/42∼45,XY,add(4)(p16),del(5)(q13q33),add(8)(p21),add(8)(q24),add(17)(p12),-18,-19,-20,+1∼3mar[cp4]. | nucish(3′MECOMx2,5′MECOMx3)(3′MECOM con 5′MECOMx2)[40/200] |
| 124 | M | 78 | AML | A, PR | 0 | 45,XY,-7[19]/46,XY[1] (cryptic) | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[42/200] |
| 125 | F | 69 | AML | D | 1 | 46,XX,add(3)(q21),inv(5)(p15q31)[20] | ish add(3)(q26)(3′MECOM+; 5′MECOM-)[2].nucish(3′MECOMx2,5′MECOMx1)(3′MECOM con 5′MECOMx1)[150/200] |
| 126 | M | 74 | CMML | D | 9 | 46,XY,del(3)(q21q25)[5]/47,XY,+12[1]/46,XY[14] | ish del(3)(q21q25)(MECOM+)[2].nucish(3′MECOMx1,5′MECOMx2)(3′MECOM con 5′MECOMx1)[5/200] |
| 127 | M | 54 | AML | D | 7 | 43-44,XY,-3,-4,add(5)(q11.2),-20,add(21)(q22),-22,+r,+1-2mar[cp20] | ish r(3′MECOM+,3′MECOM+,5′MECOM+,5′MECOM+)[3].nucish(MECOMx3)(3′MECOM sep 5′MECOMx2)[183/200] |
| 128 | F | 18 | t-MDS | D | 0 | n/a | nucish(MECOMx2)(3′MECOM sep 5′MECOMx1)[47/200] |
| 129 | M | 60 | MM; MDS | A, PR(SCT) | 27 | 41,X,-Y,+1,der(1)t(1; 14)(p13; q12)t(14; 16)(q32; q23),del(1)(p34),del(1)(q22),t(3; ?)(q26.2; ?),del(6)(q14),der(7)t(7; 8)(p21; q12),add (7)(q36),del(8)(p22),-9,dic(9; ?)(q34; ?)t(?; 11)(?; q12),psu dic(10; 1)(q26; q12),-11,del(11)(q12),-13,-14,-15,-15,der(16)t(14; 16),add(16)(q12),-17,+19,add(19)(p13),add(21)(p13)x2,-22,+1∼4mar[cp14]/46,XY[6] | nucish(3′ MECOMx2,5′ MECOMx3)(3′ MECOM con 5′ MECOMx2)(MECOM amp)[100/200] |
MM: multiple myelom; cryptic: can't be detected by chromosomal analysis
2. Experimental design, materials and methods
This is a retrospective study. A search of the cytogenetics database for MECOM FISH positive cases from May 1, 2009 to August 15, 2018 at The University of Texas MD Anderson Cancer Center (MDACC) has been performed, and a total of 129 cases with at least one time MECOM FISH positive result has been found. Other cases with 3q26 abnormality by conventional cytogenetics but negative for and/or not been confirmed for MECOM rearrangement are excluded from this study. Clinicopathologic data, including MECOM FISH test results, were collected by electronic medical chart review.
Conventional G-banded chromosomal analysis (karyotyping) has been routinely performed on unstimulated 24-h and 48-h BM aspirate cultures using standard techniques as we have reported previously [6], [7], [8]. Interphase-, metaphase-, map-back FISH and WCP have been performed by following existing laboratory protocols as reported previously [6], [7], [8], [9]. The following probe/probe set have been employed for this study. The MECOM (EVI1) dual color, breakapart (BAP) DNA probe (#KI-10204) from Leica Biosystems/Kreatech (Buffalo Grove, IL; theVysis LSI BCR/ABL ES Dual Color Fusion probe, VysisMYC BAP probe; the Vysis ETV6 BAP Probe and the VysisRUNX1T1/RUNX1 Fusion probe (Abbott Molecular, Des Plaines, IL).All these probe/probe set used for our clinical diagnosis have been validated in our laboratory in accord with the American College of Medical Genetics and Genomics (ACMGG) guidelines.
Footnotes
Transparency document associated with this article can be found in the online version at https://doi.org/10.1016/j.dib.2019.104025.
Transparency document
The following is the transparency document related to this article:
Multimedia component 1
mmc1.docx (11.4KB, docx)
References
- 1.Tang Z., Tang G., Hu S., Patel K.P., Yin C.C., Wang W., Lin P., Toruner G.A., Ok C.Y., Gu J., Lu X., Khoury J.D., Medeiros L.J. Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations. Cancer Genet. 2019;233–234:21–31. doi: 10.1016/j.cancergen.2019.03.002. [DOI] [PubMed] [Google Scholar]
- 2.Lugthart S., Groschel S., Beverloo H.B., Kayser S., Valk P.J., van Zelderen-Bhola S.L., Jan Ossenkoppele G., Vellenga E., van den Berg-de Ruiter E., Schanz U., Verhoef G., Vandenberghe P., Ferrant A., Kohne C.H., Pfreundschuh M., Horst H.A., Koller E., von Lilienfeld-Toal M., Bentz M., Ganser A., Schlegelberger B., Jotterand M., Krauter J., Pabst T., Theobald M., Schlenk R.F., Delwel R., Dohner K., Lowenberg B., Dohner H. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J. Clin. Oncol. 2010;28:3890–3898. doi: 10.1200/JCO.2010.29.2771. [DOI] [PubMed] [Google Scholar]
- 3.Groschel S., Lugthart S., Schlenk R.F., Valk P.J., Eiwen K., Goudswaard C., van Putten W.J., Kayser S., Verdonck L.F., Lubbert M., Ossenkoppele G.J., Germing U., Schmidt-Wolf I., Schlegelberger B., Krauter J., Ganser A., Dohner H., Lowenberg B., Dohner K., Delwel R. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J. Clin. Oncol. 2010;28:2101–2107. doi: 10.1200/JCO.2009.26.0646. [DOI] [PubMed] [Google Scholar]
- 4.De Braekeleer E., Douet-Guilbert N., Basinko A., Bovo C., Gueganic N., Le Bris M.J., Morel F., De Braekeleer M. Conventional cytogenetics and breakpoint distribution by fluorescent in situ hybridization in patients with malignant hemopathies associated with inv(3)(q21;q26) and t(3;3)(q21;q26) Anticancer Res. 2011;31:3441–3448. [PubMed] [Google Scholar]
- 5.De Braekeleer M., Gueganic N., Tous C., Le Bris M.J., Basinko A., Morel F., Douet-Guilbert N. Breakpoint heterogeneity in (2;3)(p15-23;q26) translocations involving EVI1 in myeloid hemopathies. Blood Cells Mol. Dis. 2015;54:160–163. doi: 10.1016/j.bcmd.2014.11.015. [DOI] [PubMed] [Google Scholar]
- 6.De Braekeleer M., Le Bris M.J., De Braekeleer E., Basinko A., Morel F., Douet-Guilbert N. 3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review. Future Oncol. 2015;11:1675–1686. doi: 10.2217/fon.15.64. [DOI] [PubMed] [Google Scholar]
- 7.Tang G., Hu S., Wang S.A., Xie W., Lin P., Xu J., Toruner G., Zhao M., Gu J., Doty M., Li S., Medeiros L.J., Tang Z. t(3;8)(q26.2;q24) often leads to MECOM/MYC rearrangement and is commonly associated with therapy-related myeloid neoplasms and/or disease progression. J. Mol. Diagn. 2018;21:343–351. doi: 10.1016/j.jmoldx.2018.10.005. [DOI] [PubMed] [Google Scholar]
- 8.Tang Z., Li Y., Wang W., Yin C.C., Tang G., Aung P.P., Hu S., Lu X., Toruner G.A., Medeiros L.J., Khoury J.D. Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. Leuk. Res. 2018;73:86–94. doi: 10.1016/j.leukres.2018.09.006. [DOI] [PubMed] [Google Scholar]
- 9.Gu J., Patel K.P., Bai B., Liu C.H., Tang G., Kantarjian H.M., Tang Z., Abraham R., Luthra R., Medeiros L.J., Lin P., Lu X. Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression. Mol. Cytogenet. 2015;8:68. doi: 10.1186/s13039-015-0171-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Multimedia component 1
mmc1.docx (11.4KB, docx)